R. Thiel

发表

Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate.

C. Hudis, L. Norton, A. Seidman, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4

P. Oberoi, D. O'Shannessy, E. Somers, 2013, Journal of Ovarian Research.

Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival.

P. Schwartz, T. Rutherford, E. Kohorn, 1999, Gynecologic oncology.

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies

F. Esteva, D. Slamon, H. Fritsche, 2005, Breast Cancer Research.

Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.

T. Stamey, D. Chan, A. Partin, 2003, The Journal of urology.

Soluble mesothelin related peptides: A potential biomarker for malignant pleural mesothelioma

N. Sardesai, H. Pass, I. Hellstrom, 2005 .

Complexed PSA performance for prostate cancer detection in an African-American population.

W. Rayford, C. Cheli, R. Thiel, 2003, Urology.

Fifth-generation digital immunoassay for prostate-specific antigen by single molecule array technology.

Lori J Sokoll, David H Wilson, Alan W Partin, 2011, Clinical chemistry.

Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract.

M F Sarosdy, E. Messing, D. Lamm, 1996, The Journal of urology.

Prognostic indicators for poor risk epithelial ovarian carcinoma

P. Schwartz, E. Kohorn, S. Chambers, 1994, Cancer.

Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment.

E. Messing, D. Lamm, P. Lange, 1996, The Journal of urology.

Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer.

C. Cuny, A. Luderer, Y. Chen, 1996, Urology.

Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression.

Farooq Ghani, Samir S Taneja, B. Shuch, 2005, The Journal of urology.

Folate Receptor Alpha Expression in Lung Cancer: Diagnostic and Prognostic Significance

S. Singhal, A. Vachani, D. O'Shannessy, 2012, Oncotarget.

65PSERUM HER-2 LEVELS AS A PREDICTOR OF CLINICAL OUTCOME IN METASTATIC BREAST CANCER (MBC) PATIENTS TREATED WITH TRASTUZUMAB-BASED THERAPIES

W. Carney, R. Thiel, 2013 .

Prostate-specific antigen velocity accurately predicts response to salvage radiotherapy in men with biochemical relapse after radical prostatectomy.

S. Taneja, H. Lepor, R. Thiel, 2005, Urology.

Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival.

P. Schwartz, T. Rutherford, E. Kohorn, 1999, Gynecologic oncology.

Multicenter comparison of the diagnostic performance of free prostate-specific antigen.

T. Stamey, J. Oesterling, D. Chan, 1996, Urology.

Clinical evaluation of a novel method for the measurement of prostate‐specific antigen, AccuPSATM, as a predictor of 5‐year biochemical recurrence‐free survival after radical prostatectomy: results of a pilot study

Lori J Sokoll, Alan W Partin, Samir S Taneja, 2012, BJU international.